Ratings Rhone Ma Holdings

Equities

RHONEMA

MYL5278OO006

End-of-day quote BURSA MALAYSIA 23:00:00 08/05/2024 BST 5-day change 1st Jan Change
0.67 MYR +2.29% Intraday chart for Rhone Ma Holdings -0.74% -2.90%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
-2.90% 31.27M -
+32.36% 695B
C+
+26.51% 568B
B
-4.40% 361B
C+
+19.46% 330B
B-
+3.50% 283B
C+
+16.34% 239B
B+
+6.68% 204B
B-
-9.08% 198B
A+
+8.62% 168B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. RHONEMA Stock
  4. Ratings Rhone Ma Holdings